MedPath

New Haven Pharmaceuticals, Inc.

New Haven Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2008-01-01
Employees
11
Market Cap
-
Website
http://www.newhavenpharma.com

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

1

FDA:1

Drug Approvals

DURLAZA

Approval Date
Sep 25, 2015
FDA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

Phase 1
Completed
Conditions
Cardiovascular Disease
Interventions
Drug: Durlaza™
First Posted Date
2015-02-25
Last Posted Date
2015-08-06
Lead Sponsor
New Haven Pharmaceuticals, Inc.
Target Recruit Count
41
Registration Number
NCT02370680
Locations
🇺🇸

Platelet and Thrombosis Research, LLC, Baltimore, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.